On 28 February 2020, Harbour BioMed announced FDA approval of its Investigational New Drug application for HBM4003, an anti-CTLA-4 antibody and candidate for the treatment of advanced solid tumours.
Med Tech Giant Handed Largest Penalty Ever Given Under the Therapeutic Goods Act
Secretary, Department of Health v Medtronic Australasia Pty Ltd [2024] FCA 1096 Date of decision: 19 September 2024 Body: Federal Court of...